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ABSTRACT
Objective: To review the surgical and oncological outcomes of patients who underwent hepatic resection for hepatocellular carcinoma (HCC).
Study Design: Cohort study.
Place and Duration of Study: Department of Surgery of the Aga Khan University Hospital Karachi, from 2008 to 2019.
Methodology: Consecutive patients who underwent hepatic resection for HCC at the Hospital were included. The data
were collected and analysed on aspects including demographics, liver function status, tumour characteristics, perioperative management, and surgical and oncological outcomes. Survival analyses were performed using the Kaplan-Meier
method, and log-rank test was applied to determine the inﬂuence of variables on overall and disease-free survival.
Results: A total of 59 patients underwent hepatic resection for HCC during the study period including 38(64%) males. The
majority of the patients had a single lesion (88%), unilobar disease (95%), underlying cirrhosis (75%) and BCLC stage B
(73%). Major hepatic resection was performed in 27(46%) patients. The mean duration of surgery was 288+101 minutes
and the mean estimated blood loss was 986+637 mls. Postoperative complications developed in 22(37%) patients
including surgical complications in 11(19%), liver decompensation in 4(7%) and systemic complications in 9(15%) patients.
The overall 30-day mortality was 7%. With a mean follow-up of 2.8 years, disease recurrence was documented in 25(42%)
patients and the median overall survival was 45 months.
Conclusion: Hepatic resection for HCC is an eﬀective treatment option in this setup. Despite low volumes, surgical and
oncological outcomes of hepatic resection for HCC were comparable to the international standards.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the sixth most common
cancer and the fourth leading cause of cancer-related death
worldwide.1 The incidence of HCC is on rise due to the
increasing prevalence of chronic hepatitis C virus (HCV) infection.2 Pakistan is ranked second in HCV burdened countries in
the world.3 Published data suggest that HCV is the underlying
risk factor for the development of HCC in 87% patients in
Pakistan.4
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A number of treatment options are available for treatment of
hepatocellular carcinoma ranging from transarterial embolisation with chemo-radiotherapy, percutaneous thermoablation,
surgical resection, and liver transplantation to various means of
palliation. Unfortunately, the majority of patients from this part
of the world have advanced disease at the time of diagnosis and
are candidates for palliative therapies only.5
In view of the absence of eﬀective chemotherapy and the insensitivity of HCC to radiotherapy, complete tumour resection in the
form of resection or transplant represents the only opportunity
for a long-term cure.6 But these options have limited application
due to various factors related to the stage of the disease at
presentation, physiological status of the liver, technical
resources and infrastructure for perioperative care.
Despite being a norm in the developed world, the underlying
cirrhosis and limited infrastructure make hepatic resection a
major challenge in the developing world. Moreover, the centres
oﬀering hepatobiliary services are only a handful, resulting in
limited published data on the surgical and oncological outcomes
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of HCC from this part of the world. This study was conducted with
the primary objective to review the surgical and oncological
outcomes of patients who underwent hepatic resection for hepatocellular carcinoma by a single hepatobiliary surgeon.

METHODOLOGY
Consecutive patients who underwent hepatic resection for HCC
at the Aga Khan University Hospital from 2008 to 2019 were
included in the study. Data were retrieved through the International Classiﬁcation of Disease (ICD)-9 coding system and
collected on a structured questionnaire including information
on demographics, liver function status, tumour characteristics,
perioperative management, and surgical and oncological
outcomes. Ethical approval was obtained from the Institutional
Ethical Review Committee for the study (ERC # 2020-544214042).

A total of 59 patients underwent liver resection for hepatocellular carcinoma during the study period. All patients who underwent liver resection for other indications during this period
were excluded. Triphasic computerised tomography scan or
multiparametric magnetic resonance imaging was performed
to assess the resectability of tumour. Surgical intervention was
oﬀered to the patients with preserved liver functions preferably
3
Child-Pugh A, platelet count of more than 100,000/mm , and
after discussion in a multidisciplinary tumour board meeting.
Additional assessment of liver function and portal hypertension was made by using Fibroscan, liver biopsy, endoscopy, and
measurement of hepatic venous pressure gradient, where indicated. Although, volumetric assessment of remnant liver was
not used routinely, a gross future liver remnant volume of at
least 40% and 30% were aimed for patients with and without
7
cirrhosis, respectively.
Patients undergoing hepatic resection received general anaesthesia with invasive monitoring. After liver mobilisation, intraoperative ultrasound was performed to assess the extent of
tumour, and its relation to vascular structures and to look for
any additional lesions in the liver. An inﬂow and outﬂow control
was achieved for the liver segment and lobes to be resected. An
intermittent Pringle manoeuver was employed. Parenchymal
transection was carried out using Harmonic scalpel, diathermy
and Cavitron Ultrasonic Surgical Aspirator (CUSA). A low CVP
was maintained intraoperatively and epidural analgesia or
patient-controlled analgesia was used for pain control.
Statistical analysis was performed using the Statistical
Package for the Social Science (SPSS) version 22.0 for windows.
Mean and standard deviation were used to assess the quantitative data and frequencies with percentages for qualitative
data. Non-parametric variables were expressed as median
with range. Survival analyses were performed using the
Kaplan-Meier method, and log-rank test was applied to determine the inﬂuence of variables on overall and disease-free
survival. A p-value of <0.05 was considered signiﬁcant at 95%
conﬁdence interval.

Table I: Demographics and perioperative details of patients.
Demographics

Number (percentages)

Gender
Male
Female
Age in years (mean ± standard
deviation)
Comorbid conditions
Yes
No
ASA* class
I and II
III and above
Cirrhosis
Yes
No
BCLC* stage
0
A
B
Number of lesions
Single
More than one
Types of hepatic resection
Right hepatectomy
Left hepatectomy
Central hepatectomy
Left lateral segmentectomy
Bisegmentectomy
Segmentectomy / non-anatomical
resection
Median duration of surgery in minutes
(range)
Median estimated blood loss in ml
(range)
Pack cell transfusion
Yes
No
Tumour size (mean ± SD)
Maximum bilirubin level postresection
(mg/dl, mean ± SD)
Median days for normalisation of
bilirubin (range)
Median length of hospital stay in days
(range)

38 (64%)
21 (36%)
57±13
35 (59%)
24 (41%)
28 (48%)
31 (52%)
44 (75%)
15 (25%)
03 (05%)
13 (22%)
43 (73%)
52 (88%)
07 (12%)
21 (35.6%)
05 (8.5%)
01 (1.7%)
07 (11.8%)
06 (10.1%)
19 (32.2%)
300 (85-570)
900 (100-3500)
22 (37%)
37 (63%)
6.6 ± 4.13
2.78 ± 6.3
1 (0-150)
9 (4-40)

*SD: Standard deviation; *ASA Score: American society of anesthesiology
score; *BCLC: Barcelona clinic liver cancer stage.

RESULTS
More than 150 total hepatic resections were performed at the
hospital during the study period for various indications,
including 59 liver resections performed for hepatocellular carcinoma. Table I summarises the demographic and perioperative
details of patients included in the current study. Table II depicts
the surgical and oncological outcomes of patients. Wound infections were managed with the opening of the wound and daily
dressings, while intraabdominal collections secondary to bile
leak were managed with image-guided drain placement and
antibiotics. No endoscopic intervention was required for the
management of bile leak in this group. Ascites wereresponsive
to diuretics and salt-free albumin in all patients, while pneumonia was managed with antibiotics and drainage of eﬀusion in
selected patients. The cause of 30-day mortality included
hepatic decompensation in three patients and acute myocardial infarction in one patient.
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Table II: Surgical and Oncological outcomes of study population.
Surgical outcomes

Numbers (percentage)

Overall Morbidity
Wound infection
Intraabdominal collection
Ascites
Encephalopathy
Pulmonary infections
Myocardial infarction
Total 30-day mortality
Liver decompensation
Myocardial infarction
Total 90-day mortality
Oncological outcomes
Resection margin
Negative (R0)
Positive (R1)
Microscopic resection margin (mean +
SD, cm)
Microvascular invasion
Present
Absent
Alpha fetoprotein
Normal
Elevated
Not known (missing data)
Type of HCC on histopathology
Well diﬀerentiated
Moderately diﬀerentiated
Poorly diﬀerentiated
Overall recurrence
Early recurrence (within two years)
Late recurrence (after two years)
Mean overall survival
Mean disease-free survival

22 (37%)
6 (10%)
5 (8%)
4 (7%)
3 (5%)
8 (14%)
1 (1.7%)
4 (7%)
3
1
7 (12%)

58 (98.3%)
01 (1.7%)
1.02 + 0.13
10 (17%)
49 (83%)
Figure 1: Prognostic signiﬁcance assessed using Kaplan-Meier survival
and log-rank tests. Kaplan-Meier survival curves showing signiﬁcantly
prolonged disease-free survival in patients with (A) absence of microvascular invasion (p= 0.001, log-rank test), (B) absence of cirrhosis
(p=0.008, log-rank test) and (C) BCLC stage A (p=0.038, log-rank test).

19 (32%)
23 (39%)
17 (29%)
15 (25.4%)
32 (54.2%)
12 (20.4%)
25 (42%)
15 (60%)
10 (40%)
45 months
9 months

Table III: Log-rank test showing the inﬂuence of variables on overall and
disease-free survival.

Microvascular invasion
Cirrhosis
BCLC stage
Size of the tumour
Alpha fetoprotein
Tumour diﬀerentiation

Disease free survival

Overall survival

0.001
0.088
0.038
0.175
0.374
0.671

0.607
0.999
0.390
0.001
0.581
0.573

A bivariate analysis was performed to identify factors associated with postoperative morbidity, 30 and 90-day mortality. A
correlation was sought for variables including gender, comorbid conditions, underlying cirrhosis of the liver, number of
lesions, and BCLC stage at presentation but no signiﬁcant associations could be identiﬁed. Similarly, the magnitude of
hepatic resection, duration of surgery, and blood loss also
failed to show any statistical correlation with immediate postoperative outcomes. Mean overall survival was 45 months and
disease-free survival was 9 months. With a mean follow-up of
2.8 years, 25 (42%) patients developed disease recurrence.
For recurrent disease, repeat surgical resection was
performed in 2 (3%) patients, trans-arterial chemoembolisation (TACE) in 8 (14%) patients and percutaneous radiofrequency ablation (RFA) in 5 (9%) patients. The other 10 patients
were lost to follow-up.
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Table III and Figure 1 (A, B, and C) depict the inﬂuence of variables on oncological outcomes including overall and diseasefree survival. Disease-free survival was signiﬁcantly associated
with absence of microvascular invasion (p=0.001), absence of
cirrhosis (p=0.008), and BCLC stage (p=0.038) on KaplanMeier survival curves and log-rank tests. However, tumour size
had no signiﬁcant association with disease-free survival but
was signiﬁcantly associated with overall survival (p=0.009).

DISCUSSION
Liver resection is a curative therapeutic modality for early HCCs
(BCLC stage A/B) with preserved liver functions.8 Asian countries including Pakistan have a high prevalence of HCC
secondary to hepatitis virus infections.9 The study centre is one
of the largest tertiary care hospitals of the country and the
authors receive a referral from centres across the country;
despite that it remains a low-volume centre for liver resection.
Out of approximately 150 liver resections performed for various
indications over the years, 59 patients underwent resection for
HCC. Despite limitations, the surgical outcomes of our patients
who underwent hepatic resection for HCC seem comparable to
the international literature.
Outcomes after surgery have association with various factors in
liver resection for HCC, including hospital and surgeon volumes
of cases per year. High-volume centres are usually considered
those performing more than 25 liver resections per year. Chang
et al. in their study including 13,159 patients from low and high-volume centres demonstrated a better short and long term
survival after hepatic resections by high volume surgeons at
high volume centres compared to low-volume surgeons in lowvolume centres.10 It emphasised on need for centralisation to a
few surgeons and hospitals to improve outcomes. The reported
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complication rate varies in the literature due to diﬀerent criteria
but an overall complication rate of 24% to 70% is reported in literature.11 The overall morbidity in this series was 37% and was
comparable to both low and high-volume centres reported in
multicentre studies.12,13 Presence of comorbid conditions and
ASA scores have also been identiﬁed as a risk factor for overall
morbidity after liver resection for HCC.14 More than half of our
patients had at least one comorbid condition like diabetes mellitus, hypertension, ischemic heart disease or chronic obstructive pulmonary disease and had ASA score more than three; but
univariate analysis failed to show any association with
morbidity or mortality.
It is interesting to note that 43 patients (73%) in this study were
classiﬁed to have BCLC stage B. The reason for inclusion in BCLC
B included the number of the lesion (more than one) in 7
patients and size of the lesion (more than 5 cm) in the remaining
35 patients. The size of the largest lesion in this study ranged
from 2.3 cm to 22 cm with a mean size of 6.6 cm. All the patients
who underwent surgical resection were in Child-Pugh Class A
and within Milan’s Criteria. The recommendations made in
BCLC guidelines suggest options other than resection for such
lesions, but several Asian and European studies have come to
the opposite conclusions.15,16 The major limitation in the region
is the availability of liver transplantation as a ﬁrst-line treatment option for intermediate stage HCC falling in the category
of BCLC B. Another interesting area of debate is the huge size
tumours falling beyond the traditional transplant criteria but
patients have preserved liver function. There is convincing data
available to support the fact that hepatic resection may be
considered as the ﬁrst-line treatment option in this speciﬁc
group of patients because of its associated survival
advantage.17 The present results support the suggestion that
comparable outcomes can be achieved in selected patients
with intermediate-stage HCC who underwent hepatic resection
as the ﬁrst-line treatment option.
Perioperative blood loss not only adversely aﬀects the morbidity
after hepatic resection including the risk of post hepatectomy
liver failure, but it also has been shown that massive blood loss
and blood transfusions increase the risk of tumour recurrence in
HCC patients.18,19Intraoperative blood loss in this series was relatively high compared to high-volume centres, but still
comparable to low-volume cantres performing hepatic resections. Cawich et al. and Meir et al. reported blood loss of 1405 ml
and 1090 ml respectively in their series of patients at low-volume
12,20
centres.
Factors associated with increased blood loss in our
setup are the lack of sophisticated devices for bloodless surgery
and the presence of cirrhosis in majority of the authors’ patients.
A study by Lee et al. demonstrated that blood loss of more than
800 ml was an independent risk for major surgical complications
11
after hepatectomy for HCC. Daniel et al. reported operative
time more than 180 minutes as an independent factor for major
postoperative complications in an analysis of 156 patient under21
going hepatic resection, but no such association was found in
this study. The operative time in this study was comparable with
low-volume contemporary series but higher than high-volume

21

centres. One potential reason for the longer duration of surgery
is the ongoing training of residents and fellows in major surgical
procedures, as the institution is a teaching hospital with general
surgery residency and fellowship programs to train future
surgeons.
Despite recent advancements in liver surgery techniques, novel
devices for bloodless surgery and evolving postoperative care,
there is substantial risk associated with the procedure. Recent
studies reported perioperative mortality rates of 2.6% to 8.4%
22
for HCC patients. The deﬁnition of perioperative mortality in
most studies was hospital mortality or death within 30 days after
the operation. The 30-day mortality was 7% which is comparable
to other studies for patients with HCC.
The median recurrence-free survival was lower than other
studies due to the higher number of patients in BCLC stage B in
this series.23 Recurrence was seen in 42% patients and more than
half of our patients had early recurrence within two years of resection. Patients with microvascular invasion and BCLC stage B had
signiﬁcantly lower disease-free survival than their counterparts
and these ﬁndings have already been seen in other studies.24
Locoregional therapies and resections were performed in
patients after recurrence which can prolong the overall survival.

CONCLUSION
Despite low volumes and limited infrastructure, surgical and
oncological outcomes of hepatic resection for HCC at the centre
are comparable to the international standards. Factors associated with poor oncological outcomes include the presence of
cirrhosis, microvascular invasion and BCLC stage B.
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